XNASCKPT
Market cap175mUSD
Dec 24, Last price
3.55USD
1D
2.82%
1Q
62.50%
IPO
-92.72%
Name
Checkpoint Therapeutics Inc
Chart & Performance
P/E
—
P/S
1,658.94
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
45.69%
Rev. gr., 5y
-50.61%
Revenues
103k
-46.35%
Net income
-52m
L-22.52%
CFO
-48m
L-17.31%
Earnings
Mar 20, 2025
Profile
Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells. It is also developing Olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a treatment for patients with EGFR mutation-positive non-small cell lung cancer; CK-103, a selective and potent small molecule inhibitor of bromodomain and extra-terminal bromodomains; and anti-carbonic anhydrase IX (CAIX) antibody, a fully human preclinical antibody to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has collaboration agreements with TG Therapeutics, Inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 103 -46.35% | 192 -28.36% | 268 -74.93% | ||||||
Cost of revenue | 95,817 | 108,750 | 105,444 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | (95,714) | (108,558) | (105,176) | ||||||
NOPBT Margin | |||||||||
Operating Taxes | 4,291 | (53) | |||||||
Tax Rate | |||||||||
NOPAT | (95,714) | (112,849) | (105,123) | ||||||
Net income | (51,847) -22.52% | (66,915) 18.19% | (56,617) 146.58% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 33,621 | 14,881 | 41,279 | ||||||
BB yield | -78.33% | -32.96% | -17.46% | ||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | 20,297 | ||||||||
Net debt | (4,928) | (12,068) | (54,735) | ||||||
| Cash flow | |||||||||
Cash from operating activities | (47,590) | (57,554) | (26,306) | ||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | 40,450 | 14,887 | 40,269 | ||||||
FCF | (102,150) | (93,366) | (105,123) | ||||||
| Balance | |||||||||
Cash | 4,928 | 12,068 | 54,735 | ||||||
Long term investments | |||||||||
Excess cash | 4,923 | 12,058 | 54,722 | ||||||
Stockholders' equity | (314,330) | (260,600) | (193,255) | ||||||
Invested Capital | 301,283 | 241,117 | 223,001 | ||||||
ROIC | |||||||||
ROCE | 733.61% | 557.19% | |||||||
| EV | |||||||||
Common stock shares outstanding | 18,742 | 8,836 | 7,603 | ||||||
Price | 2.29 -55.19% | 5.11 -83.57% | 31.10 17.36% | ||||||
Market cap | 42,920 -4.94% | 45,150 -80.91% | 236,458 59.82% | ||||||
EV | 37,992 | 33,082 | 181,723 | ||||||
EBITDA | (95,714) | (108,558) | (105,176) | ||||||
EV/EBITDA | |||||||||
Interest | 4,291 | ||||||||
Interest/NOPBT | |||||||||